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sequencing, was also used to confirm the base calls of these
100 SNPs. The visual inspection of the electropherograms
and the sequencing independent method were in good
agreement and indicated that 80 (91%) of 88 successful
assays of the nucleotide differences were genuine.
Since our initial report, we have improved our methods
for overlaying the annotation of open reading frame coordi-
nates onto our analysis of the coordinates of nucleotide
substitutions. Approximately 7% of the genome is noncod-
ing, and approximately 15% of the substitutions are in
these regions.
Dr. Musser is correct in pointing out that the substitu-
tion frequency expressed in Fraser et al. (5), based on our
preliminary annotation of our M. tuberculosis sequence
data, is not an equivalent comparison to the synonymous
substitution frequency derived by his method of sequencing
a select set of genes over a wide range of M. tuberculosis
strains. He uses the methods of Li et al. (6), among the most
widely accepted, for the calculation of nucleotide substitu-
tion frequencies and derives a Ds value of <0.01 synonymous
substitutions per 100 synonymous sites. Our preliminary
data presented the frequency of total nucleotide substitu-
tions at all positions (coding [synonymous and nonsynony-
mous] and noncoding) of the two recently sequenced strains,
H37Rv and CDC1551. Our manuscript in preparation
comparing the two M. tuberculosis strains will contain an
analysis of synonymous substitutions. However, while Dr.
Musser compared a select group of genes over perhaps
several hundred strains, our frequency will be based on a
genome-wide comparison between two strains.
Robert Fleischmann
The Institute for Genomic Research
Rockville, Maryland, USA
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Will Avilamycin Convert Ziracine into Zerocine?
To the Editor: Dr. Courvalin urges that avilamycin be
prospectively banned as an antibiotic growth promoter to
prevent the development of bacteria cross-resistant to the
potential human-use product evernimicin (1). Elanco
Animal Health, the manufacturer of avilamycin, would like
to clarify the situation with respect to avilamycin and
everninomicin. It should be noted that there is incomplete
cross-resistance in that enterococci resistant to avilamycin
exhibit only decreased susceptibility, not complete resis-
tance, to everninomicin (2). Dr. Courvalin’s recommenda-
tion has become moot, since Schering-Plough has discontin-
ued clinical development of Ziracin, as announced in early
May 2000, “because the balance between efficacy and safety
did not justify further development of the product” (http://
www.sch-plough.com/news/research/2000/050500.html).
Thus, avilamycin actually remains in compliance with the
Swann principles. In addition, the Scientific Committee on
Animal Nutrition, which advises the European Union
Commission, released its assessment of the potential
impact from cross-resistance in late April 2000 (http://
www.europa.eu.int/comm/food/fs/sc/scan/out48_en.pdf) and
concluded that, although transfer of resistant bacteria–and
presumably resistance genes–from animal to human
bacteria is possible, the magnitude of the transfer with
avilamycin resistance was not possible to predict. In part,
this conclusion reflected the early developmental status of
Ziracin and a few reports of clinical experience. An exten-
sive survey of Ziracin showed that 100% of 4,208 enterococ-
cal isolates from patients in 27 European countries were
susceptible (3). Another survey of Ziracin showed that
99.5%-100% of 6,030 isolates of methicillin-resistant
Staphylococcus aureus/epidermidis, enterococci, streptococ-
ci, and pneumococci from 33 laboratories around the world
were susceptible (4). Avilamycin has been used in animal
production in many of the countries from which these
clinical isolates originated. To fairly balance a preemptive
precautionary action against a currently marketed animal
use product and a human clinical candidate, the World
Health Organization Global Principles recommended that
such an action be initiated only when the human clinical
candidate dossier is submitted for regulatory approval, to
ensure that the candidate will indeed enter the market-
place. (Use of antimicrobial growth promoters that belong to
classes of antimicrobial agents used or submitted for
approval in humans and animals should be terminated or
rapidly phased out in the absence of risk-based evalua-
tions.) [http://www.who.int/emc/diseases/zoo/
who_global_principles.html#Purpose]). This recommenda-
tion also acknowledges, in accordance with the Swann
Principles, that antimicrobial agents intended for nonhu-
man use can be used in animal production. The modifica-
tion by the pharmaceutical industry of older classes of
antimicrobials for human clinical use, with counterparts
previously developed by animal health companies for use as
growth promoters, has become common. Dr. Aarestrup of
the Danish Veterinary Laboratory commented that “it will
be necessary in the future to either totally avoid the use of
antimicrobials for growth promotion or, once antimicrobials
have been approved for growth promotion, to reserve these
classes for growth promotion and search for therapeutic
options among other classes” (2). With respect to avilamy-
cin, this latter option is the better one, now that evernino-
micin (and perhaps the entire orthosomycin class by
extension) has been demonstrated to be unsafe for parenter-
al or injectable use in humans, because it allows animal
producers to use a product that poses no resistance threat to
public health. Finally, other unique antibiotics for treatmentLetters
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of serious gram-positive infections in humans (with no
animal use counterparts) are in the pharmaceutical pipe-
line (e.g., LY333328 and daptomycin) or have recently been
approved (e.g., linezolid). We hope that a fair balance can be
achieved by the human medical and the animal health and
production communities with regard to the types of antimi-
crobial agents that can be used in each sector.
Thomas R. Shryock
Elanco Animal Health, Greenfield, Indiana, USA
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The Antibiotic Food-Chain Gang
To the Editor: In his reply to my letter (1), Dr. Shryock
states that use of the growth promoter avilamycin, which
confers cross-resistance to other members of the evernino-
mycin class of drugs, was in compliance with the Swann
principles. The Swann report, issued in 1969, recommends
that antibiotics used to treat infections in humans not be
used as animal-food additives (2). The combined efforts of
many scientists were needed to bring about the 1999 ban in
Europe of spiramycin, tylosin, virginiamycin, and bacitra-
cin, each of which confers resistance to antibiotics used in
clinical settings. It appears that more than 30 years was
necessary for the animal-food industry to act in accordance
with the Swann report.
The reasoning in terms of drug structures can be
misleading. The implication is that drugs that are chemical-
ly closely related have the same target of action and are
therefore subject to cross-resistance, and vice versa. For
example, because it has an unusual structure, apramycin (a
4-substituted-2-deoxystreptamin) was used exclusively in
animals in the hope that it would not be recognized by any
of the known aminoglycoside-modifying enzymes (3).
However, enterobacteria of animal origin were resistant to
apramycin by synthesis of a plasmid-mediated 3-N-ami-
noglycoside acetyltransferase type IV, which also confers
resistance to gentamicin (4). Following spread in animal
strains (5), the plasmid was later found in clinical isolates
from hospitalized patients (6).
The use of antibiotics in general should be based on the
mechanisms of resistance in bacteria, rather than on their
chemical makeup. In particular, the concept that resistance
was a class phenomenon rapidly lost favor because of the
extension of the concept of cross-resistance and the in-
creased occurrence of co-resistance.
In classical cross-resistance, a single biochemical
mechanism confers resistance to a single class of drugs: use
of a given antibiotic can select resistance to other members
of the group but not to drugs belonging to other classes.
However, cross-resistance between drug classes can occur
by two mechanisms: overlapping targets and drug efflux. An
example of target overlap is provided by the macrolides,
lincosamides, and streptogramins (MLS), which are chemi-
cally distantly related. However, constitutive methylation of
a single adenine residue in ribosomal RNA confers high-
level resistance to the three classes of antibiotics. This
resistance phenotype is due to the fact that all these
antibiotics have overlapping targets on the ribosome (7).
Active efflux of the drugs outside bacteria has recently been
recognized as a common resistance mechanism (8,9). This
energy-dependent export confers low-level resistance to a
wide variety of antibiotics. The broad substrate specificities
of the pumps account for decreased susceptibility to beta-
lactams, aminoglycosides, tetracyclines, chloramphenicol,
trimethoprim, sulfonamides, fluoroquinolones, and MLS,
among others (9).
In contrast to cross-resistance, co-resistance is due to
the presence in the same host of several mechanisms, each
conferring resistance to a given class of drugs. In addition,
the corresponding genes are often adjacent (physically
linked) and expressed in a coordinated fashion. One of the
most efficient system of this type is represented by the
integrons (10) first described in gram-negative bacilli
(11,12) and more recently found in gram-positive bacteria
(13). Because of the genetic organization resulting in co-
expression of the various genes, use of any antibiotic that is
a substrate for one of the resistance mechanism will co-
select for resistance to the others and thus for maintenance
of the entire gene set. Since cross-resistance means cross-
selection and co-resistance implies co-selection, the use of
any antimicrobial agent is de facto rendered inadequate as
a growth promoter.
I also disagree with the notion that because a member
of an antibiotic class has been misused as a growth promot-
er the class should not be used in the future for human
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